Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Christiansen (Winnipeg, Canada), K. Wentlandt (Toronto, Canada), J. Lew (Toronto, Canada), J. Granton (Toronto, Canada). Late Breaking Abstract - Morphine for dyspnea in advanced pulmonary arterial hypertension. 3948

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Implication of the KATP Sur2b/Kir6.1 in the physiopathology of pulmonary arterial hypertension Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Late Breaking Abstract - Contribution of STIM-activated TRPC-ORAI channels to the intermittent hypoxia-induced pulmonary hypertension Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Limited and heterogeneous arterial narrowing in idiopathic pulmonary hypertension: Rethinking resistance Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Late Breaking Abstract - Feasibility of instrumented ventilatory and functional evaluation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Pulmonary rehabilitation in asthma and COPD Year: 2021 LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs Source: Annual Congress 2013 –New physiologic boundaries Year: 2013 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Prognostic role of excessive exercise ventilation in non-operable patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2016 – Mechanisms of symptoms and exercise limitation in health and disease Year: 2016 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Exertional dyspnoea in pulmonary arterial hypertension Source: Eur Respir Rev, 26 (145) 170039; 10.1183/16000617.0039-2017 Year: 2017 The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014